HUMACYTE INC
Humacyte, Inc. (HUMA) is a clinical‑stage biotechnology company developing off‑the‑shelf, human acellular vessels (HAVs) intended to serve as living vascular grafts for people with vascular disease. The technology aims to provide a scalable, implantable conduit for indications such as dialysis access, peripheral arterial disease and surgical bypass. As a small‑cap, clinical‑stage company (market capitalisation around $320m), Humacyte’s value is driven by clinical trial outcomes, regulatory decisions and potential commercial partnerships rather than steady revenue. This profile means shares can be volatile and outcomes binary: positive clinical data or approvals could materially advance prospects, while setbacks may reduce valuation. Investors should consider clinical and regulatory risk, cash runway and dilution potential from future financing. This is educational information only and not financial advice — suitability depends on personal circumstances and investors may lose part or all of their investment.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Humacyte's stock with a target price of $10.42, indicating strong growth potential.
Financial Health
Humacyte is generating modest revenue and cash flow, but faces challenges in profitability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring HUMA
3D-Bioprinted Tissues
These cutting-edge companies are building the future of medicine by printing living human tissues layer by layer. Selected by expert analysts, this collection represents one of healthcare's most promising frontiers with potential to revolutionize transplantation and drug development.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical Catalysts Ahead
Trial readouts and regulatory milestones can move the share price significantly, though clinical outcomes are uncertain and binary in nature.
Regenerative Innovation
Off‑the‑shelf human acellular vessels address clear clinical needs and could attract partners, yet commercialisation and manufacturing scale‑up carry execution risk.
Potential Market Reach
Applications include dialysis access and vascular surgery across global markets, but adoption depends on clinical evidence, reimbursement and surgeon preference.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.